Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Potential Effects of Cannabigerol in Adolescents With Attention-Deficit/Hyperactivity Disorder
NCT07592390Phase 2Recruiting
- Sponsor
- Unisul
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Full-spectrum CBG oil 30 mg/mL with Placebo (MCT oil) (2 arms). Primary endpoint: Swanson, Nolan and Pelham Questionnaire, version IV at Week 12. Started May 2026; status: recruiting.
02
Drugs
cannabigerol
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07592390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07592390.